Rare diseases are attracting renewed interest as multinational drugmakers seek to take advantage of easier approval pathways and high prices for orphan drugs. Firms including Sanofi, Pfizer and GlaxoSmithKlein are working on or have already secured approval for drugs that treat rare conditions. The progress in understanding the molecular base for these diseases has also spurred drugmakers' interest.

Related Summaries